Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock

AGOURA HILLS, CA—Mpofu Shephard, Chief Medical (TASE:BLWV) Officer of Acelyrin, Inc. (NASDAQ:SLRN), a clinical-stage biotech company with a market capitalization of $284 million, recently sold 3,211 shares of the company’s common stock, according to a recent regulatory filing. The transaction, which took place on March 17, 2025, was executed at a weighted average price of $2.744 per share, resulting in a total sale value of approximately $8,810. According to InvestingPro analysis, the stock appears undervalued despite falling 47% over the past six months.

Following this transaction, Shephard retains direct ownership of 121,789 shares in the company. The sale was conducted to satisfy tax obligations incurred from the vesting and settlement of certain restricted stock units, as per the company’s policy, and was not a discretionary sale by Shephard.

The shares were sold in multiple transactions, with prices ranging between $2.71 and $2.76. Shephard has committed to providing full details of the individual transactions upon request.

In other recent news, Acelyrin Inc. has announced several significant developments. The company confirmed an unsolicited buyout proposal from Concentra Biosciences, which includes an offer to purchase all outstanding shares at $3.00 each, alongside a contingent value right. Meanwhile, Acelyrin is also navigating a merger with Alumis Inc., expected to conclude in the second quarter of 2025. In another strategic move, Acelyrin has terminated its License and Collaboration Agreement with Affibody AB, which involved the development of izokibep, marking a shift in their product pipeline.

Additionally, Acelyrin has implemented a stockholder rights plan in response to Tang Capital Partners (WA:CPAP) acquiring an 8.8% stake in the company. Analyst firms have also made adjustments to Acelyrin’s stock targets. Citi reduced its price target from $6.00 to $3.00, maintaining a Neutral rating due to uncertainties surrounding the Phase 3 program for lonigutamab, a treatment for thyroid eye disease. H.C. Wainwright also lowered its price target from $8.00 to $6.00, citing recent data from the Phase 1/2 study of lonigutamab and the forthcoming Phase 3 program. These developments reflect the dynamic landscape Acelyrin is navigating, with various strategic decisions and market reactions shaping its future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.